This time, in Q3FY19, expect a revenue growth of 15 percent odd for Glenmark Pharma with EBITDA growth of around 36 percent. Thus, there should be some amount of improvement in the margins on a year-on-year (YoY) basis to 17.4 versus 14.6 percent with the profit at around Rs 225 crore odd. However, the profit is going to escalate on the back of low base as the profit was down 75 percent during Q3FY18.
The US business would be the most important thing to watch out for this company because in Q3FY18, the US business was down 40 percent on YoY basis. Therefore, the low base has aided them in Q2 of FY19 where the US business had picked up to 11.4 percent growth after declining for 4 quarters. So, the hope is that the kind of momentum is going to sustain for Glenmark in this quarter as well.
Furthermore, US and India will be the key focus markets for the company, with regards to out licensing opportunities where they have already done 3-4 regional out licensing deals in the quarter gone by.